FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2515773670> ?p ?o ?g. }

• W2515773670 endingPage "889" @default.
• W2515773670 startingPage "882" @default.
• W2515773670 abstract "The presence of pulmonary hypertension (PH) severely aggravates the clinical course of heart failure with preserved ejection fraction (HFPEF) resulting in substantial morbidity and mortality. So far, neither established heart failure therapies nor pulmonary vasodilators have proven to be effective for this condition. Riociguat (Adempas®, BAY 63-2521), a stimulator of soluble guanylate cyclase, is a novel pulmonary and systemic vasodilator that has been approved for the treatment of precapillary forms of PH. With regard to postcapillary PH, the DILATE-1 study was a multicenter, double-blind, randomized, placebo-controlled single-dose study in subjects with PH associated with HFPEF. Although there was no significant change in the primary outcome measure, peak decrease in mean pulmonary artery pressure with riociguat versus placebo, riociguat significantly increased stroke volume without changing heart rate, pulmonary artery wedge pressure, transpulmonary pressure gradient or pulmonary vascular resistance. The present study is designed to test the efficacy of long-term treatment with riociguat in patients with PH associated with HFPEF.The DYNAMIC study is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical phase IIb trial evaluating the efficacy, safety and kinetics of riociguat in PH-HFPEF patients. The drug will be given over 26 weeks to evaluate the effects of riociguat versus placebo. The primary efficacy variable will be the change from baseline in cardiac output at rest, measured by right heart catheter after 26 weeks of study drug treatment. Additional efficacy variables will be changes from baseline in further hemodynamic parameters, changes in left and right atrial area, right ventricular volume, as well as right ventricular ejection fraction measured by cardiac magnetic resonance imaging, and changes from baseline in World Health Organization (WHO) class and N‑terminal prohormone B‑type natriuretic peptide (NT-proBNP). The trial was registered on 25 August 2014 (EudraCT Number: 2014-003055-60; www.clinicaltrialsregister.eu )." @default.
• W2515773670 created "2016-09-16" @default.
• W2515773670 creator A5008120279 @default.
• W2515773670 creator A5015640081 @default.
• W2515773670 creator A5042270393 @default.
• W2515773670 creator A5051326153 @default.
• W2515773670 creator A5051510974 @default.
• W2515773670 creator A5052959072 @default.
• W2515773670 creator A5058277260 @default.
• W2515773670 creator A5063709652 @default.
• W2515773670 creator A5079419308 @default.
• W2515773670 creator A5082533093 @default.
• W2515773670 creator A5086013885 @default.
• W2515773670 creator A5090811176 @default.
• W2515773670 date "2016-09-02" @default.
• W2515773670 modified "2023-09-25" @default.
• W2515773670 title "Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction" @default.
• W2515773670 cites W122121821 @default.
• W2515773670 cites W164205712 @default.
• W2515773670 cites W1984243104 @default.
• W2515773670 cites W2028148874 @default.
• W2515773670 cites W2040541893 @default.
• W2515773670 cites W2054214551 @default.
• W2515773670 cites W2054935021 @default.
• W2515773670 cites W2101698537 @default.
• W2515773670 cites W2107011819 @default.
• W2515773670 cites W2110055179 @default.
• W2515773670 cites W2127994875 @default.
• W2515773670 cites W2136811556 @default.
• W2515773670 cites W2148910374 @default.
• W2515773670 cites W2153739004 @default.
• W2515773670 cites W2164227851 @default.
• W2515773670 cites W2166504467 @default.
• W2515773670 cites W2319534362 @default.
• W2515773670 cites W2475261460 @default.
• W2515773670 cites W4230293260 @default.
• W2515773670 cites W4377232207 @default.
• W2515773670 cites W46115907 @default.
• W2515773670 doi "https://doi.org/10.1007/s00508-016-1068-8" @default.
• W2515773670 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5161763" @default.
• W2515773670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27590259" @default.
• W2515773670 hasPublicationYear "2016" @default.
• W2515773670 type Work @default.
• W2515773670 sameAs 2515773670 @default.
• W2515773670 citedByCount "20" @default.
• W2515773670 countsByYear W25157736702016 @default.
• W2515773670 countsByYear W25157736702017 @default.
• W2515773670 countsByYear W25157736702018 @default.
• W2515773670 countsByYear W25157736702019 @default.
• W2515773670 countsByYear W25157736702020 @default.
• W2515773670 countsByYear W25157736702021 @default.
• W2515773670 countsByYear W25157736702022 @default.
• W2515773670 countsByYear W25157736702023 @default.
• W2515773670 crossrefType "journal-article" @default.
• W2515773670 hasAuthorship W2515773670A5008120279 @default.
• W2515773670 hasAuthorship W2515773670A5015640081 @default.
• W2515773670 hasAuthorship W2515773670A5042270393 @default.
• W2515773670 hasAuthorship W2515773670A5051326153 @default.
• W2515773670 hasAuthorship W2515773670A5051510974 @default.
• W2515773670 hasAuthorship W2515773670A5052959072 @default.
• W2515773670 hasAuthorship W2515773670A5058277260 @default.
• W2515773670 hasAuthorship W2515773670A5063709652 @default.
• W2515773670 hasAuthorship W2515773670A5079419308 @default.
• W2515773670 hasAuthorship W2515773670A5082533093 @default.
• W2515773670 hasAuthorship W2515773670A5086013885 @default.
• W2515773670 hasAuthorship W2515773670A5090811176 @default.
• W2515773670 hasBestOaLocation W25157736701 @default.
• W2515773670 hasConcept C126322002 @default.
• W2515773670 hasConcept C142724271 @default.
• W2515773670 hasConcept C146556889 @default.
• W2515773670 hasConcept C164705383 @default.
• W2515773670 hasConcept C178853913 @default.
• W2515773670 hasConcept C203092338 @default.
• W2515773670 hasConcept C204787440 @default.
• W2515773670 hasConcept C27081682 @default.
• W2515773670 hasConcept C2776304953 @default.
• W2515773670 hasConcept C2777099384 @default.
• W2515773670 hasConcept C2777428986 @default.
• W2515773670 hasConcept C2778198053 @default.
• W2515773670 hasConcept C2780930700 @default.
• W2515773670 hasConcept C2780940725 @default.
• W2515773670 hasConcept C535046627 @default.
• W2515773670 hasConcept C58245268 @default.
• W2515773670 hasConcept C71924100 @default.
• W2515773670 hasConcept C78085059 @default.
• W2515773670 hasConcept C80461066 @default.
• W2515773670 hasConcept C84393581 @default.
• W2515773670 hasConceptScore W2515773670C126322002 @default.
• W2515773670 hasConceptScore W2515773670C142724271 @default.
• W2515773670 hasConceptScore W2515773670C146556889 @default.
• W2515773670 hasConceptScore W2515773670C164705383 @default.
• W2515773670 hasConceptScore W2515773670C178853913 @default.
• W2515773670 hasConceptScore W2515773670C203092338 @default.
• W2515773670 hasConceptScore W2515773670C204787440 @default.
• W2515773670 hasConceptScore W2515773670C27081682 @default.
• W2515773670 hasConceptScore W2515773670C2776304953 @default.
• W2515773670 hasConceptScore W2515773670C2777099384 @default.
• W2515773670 hasConceptScore W2515773670C2777428986 @default.

• next